Abstract Details

Title Systematic Evaluation of Dimethyl Fumarate induced Lymphopenia in Multiple Sclerosis (MS) Patients.

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 204

Objective To systematically investigate the occurrence and risk factors of lymphopenia associated with the Dimethyl Fumarate (DMF) among patients with multiple sclerosis (MS) using real-world evidence

Background DMF is one of the most prescribed oral disease modifying treatment for MS with good compliance and efficacy. However, one major side effects of DMF is the lymphopenia. Clinical risk factors associated with DMF induced lymphopenia remain to be elucidated.

Design/Methods MS patients on DMF were identified from electronic health records (EHR). Patient on prior immunomodulatory therapy and cancer patients were excluded. Demographics, BMI, DMF medication start and end date, longitudinal laboratory tests of the complete blood count with differential (CBC) were extracted from the EHR. Lymphopenia grades were defined as: Grade1: absolute lymphocytes count (ALC) between 800-1000/ul; Grade 2: ALC between 500 to 799; Grade 3: ALC <500/ul. We used two-tailed t-test for continuous variables and chi-square test for categorical variables.

Results 648 MS patients were identified who have been on DMF. 419 patient had baseline and one-year follow up CBC with differential completed and without baseline lymphopenia. 120 (28.6%) patients were identified with lymphopenia and were graded. Older patients were typically more likely to have lymphopenia as compared to younger patients. Baseline ALC levels were predictive of having more lymphopenia with similar trend seen in the different lymphopenia groups. In terms of the BMI, sex and races, there were no differences noted.

Conclusions Our study implicated that careful monitoring of ALC should be noted when DMF is administrated to patients with older age and low baseline ALC.

Authors/Disclosures
Muhammad Taimur A. Malik, MD (St Lukes) PRESENTER	Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech . Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen . Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD serono. The institution of Dr. Malik has received research support from National MS Society .
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��